DOI QR코드

DOI QR Code

Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis

  • Yu, Su Jong (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Yoon, Jung-Hwan (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Kim, Won (Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Lee, Jeong Min (Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine) ;
  • Lee, Yun Bin (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Cho, Yuri (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Lee, Dong Hyeon (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Lee, Minjong (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Yoo, Jeong-Ju (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Cho, Eun Ju (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Lee, Jeong-Hoon (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Kim, Yoon Jun (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Kim, Chung Yong (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine)
  • Received : 2015.08.11
  • Accepted : 2015.09.06
  • Published : 2017.03.01

Abstract

Background/Aims: Liver transplantation offers the only definite cure for cirrhosis but lacking donors is problem. Stem cell therapy is attractive in this setting. In this study, we aimed to explore the safety and efficacy of ultrasound-guided percutaneous portal transplantation of peripheral blood monocyte cell (PBMC) in cirrhotic patients. Methods: A total of nine decompensated cirrhotic patients were randomized into three groups: group 1 (n = 3) was control group, group 2 (n = 3) received granulocyte-colony stimulating factor (G-CSF) mobilization for 3 days, and group 3 (n = 3) received G-CSF mobilized PBMCs by leukapheresis and PBMC transplantation through ultrasound-guided percutaneous portal vein puncture. Liver function and clinical features were evaluated. Results: At baseline, the Child-Turcotte-Pugh and the model for end-stage liver disease scores were comparable in study groups. Compared with group 1, there was a tendency to improve liver function in group 3 at 6 months after treatment. Treatment was tolerable and no complications were encountered related to the G-CSF mobilization or percutaneous portal administration of PBMCs. Imaging studies showed patent portal veins at the end of the study period. Conclusions: Autologous PBMC transplantation through ultrasound-guided percutaneous portal vein puncture could be considered as a safe alternative treatment for decompensated cirrhotic patients.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-182. https://doi.org/10.1016/j.jhep.2009.11.007
  2. Han Y, Yan L, Han G, et al. Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-stimulating factor mobilization therapy. Cytotherapy 2008;10:390-396. https://doi.org/10.1080/14653240802129901
  3. Pai M, Zacharoulis D, Milicevic MN, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol 2008;103:1952-1958. https://doi.org/10.1111/j.1572-0241.2008.01993.x
  4. Lagasse E, Connors H, Al-Dhalimy M, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000;6:1229-1234. https://doi.org/10.1038/81326
  5. Korbling M, Katz RL, Khanna A, et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002;346:738-746. https://doi.org/10.1056/NEJMoa3461002
  6. Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology 2000;32:11-16.
  7. Alison MR, Poulsom R, Jeffery R, et al. Hepatocytes from non-hepatic adult stem cells. Nature 2000;406:257. https://doi.org/10.1038/35018642
  8. Grove JE, Bruscia E, Krause DS. Plasticity of bone marrow-derived stem cells. Stem Cells 2004;22:487-500. https://doi.org/10.1634/stemcells.22-4-487
  9. Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006;24:2292-2298. https://doi.org/10.1634/stemcells.2005-0542
  10. Yannaki E, Anagnostopoulos A, Kapetanos D, et al. Last-ing amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol 2006;34:1583-1587. https://doi.org/10.1016/j.exphem.2006.06.012
  11. am Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005;23:463-470. https://doi.org/10.1634/stemcells.2004-0283
  12. Gordon MY, Levicar N, Pai M, et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 2006;24:1822-1830. https://doi.org/10.1634/stemcells.2005-0629
  13. Yan L, Han Y, Wang J, Liu J, Hong L, Fan D. Peripheral blood monocytes from patients with HBV related decompensated liver cirrhosis can differentiate into functional hepatocytes. Am J Hematol 2007;82:949-954. https://doi.org/10.1002/ajh.21030
  14. Suresh K. An overview of randomization techniques: an unbiased assessment of outcome in clinical research. J Hum Reprod Sci 2011;4:8-11. https://doi.org/10.4103/0974-1208.82352
  15. Levicar N, Pai M, Habib NA, et al. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif 2008;41 Suppl 1:115-125.
  16. Kharaziha P, Hellstrom PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009;21:1199-1205. https://doi.org/10.1097/MEG.0b013e32832a1f6c
  17. Campard D, Lysy PA, Najimi M, Sokal EM. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 2008;134:833-848. https://doi.org/10.1053/j.gastro.2007.12.024
  18. Teramoto K, Asahina K, Kumashiro Y, et al. Hepatocyte differentiation from embryonic stem cells and umbilical cord blood cells. J Hepatobiliary Pancreat Surg 2005;12:196-202. https://doi.org/10.1007/s00534-005-0980-5
  19. Piscaglia AC, Campanale M, Gasbarrini A, Gasbarrini G. Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Int 2010;2010:259461.
  20. Margini C, Vukotic R, Brodosi L, Bernardi M, Andreone P. Bone marrow derived stem cells for the treatment of endstage liver disease. World J Gastroenterol 2014;20:9098-9105.
  21. Lorenzini S, Gitto S, Grandini E, Andreone P, Bernardi M. Stem cells for end stage liver disease: how far have we got? World J Gastroenterol 2008;14:4593-4599. https://doi.org/10.3748/wjg.14.4593
  22. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 2004;39:1477-1487. https://doi.org/10.1002/hep.20214
  23. Mallet VO, Gilgenkrantz H. Mobilizing stem cells to repair liver after surgery: dream or reality? J Hepatol 2005;43:754-756. https://doi.org/10.1016/j.jhep.2005.07.010
  24. de Wynter EA, Buck D, Hart C, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in longterm culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells 1998;16:387-396. https://doi.org/10.1002/stem.160387
  25. Mizunaga Y, Terai S, Yamamoto N, et al. Granulocyte colony-stimulating factor and interleukin-1$\beta$ are important cytokines in repair of the cirrhotic liver after bone marrow cell infusion: comparison of humans and model mice. Cell Transplant 2012;21:2363-2375. https://doi.org/10.3727/096368912X638856
  26. Jin SZ, Meng XW, Sun X, et al. Granulocyte colony-stimulating factor enhances bone marrow mononuclear cell homing to the liver in a mouse model of acute hepatic injury. Dig Dis Sci 2010;55:2805-2813. https://doi.org/10.1007/s10620-009-1117-5
  27. Picardi M, De Rosa G, Selleri C, et al. Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. Haematologica 2003;88:794-800.
  28. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999;353:555.
  29. Lorenzini S, Isidori A, Catani L, et al. Stem cell mobilization and collection in patients with liver cirrhosis. Aliment Pharmacol Ther 2008;27:932-939. https://doi.org/10.1111/j.1365-2036.2008.03670.x
  30. Gaia S, Smedile A, Omede P, et al. Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol 2006;45:13-19. https://doi.org/10.1016/j.jhep.2006.02.018
  31. Di Campli C, Zocco MA, Saulnier N, et al. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis 2007;39:1071-1076. https://doi.org/10.1016/j.dld.2007.08.006
  32. Spahr L, Lambert JF, Rubbia-Brandt L, et al. Granulocyte- colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology 2008;48:221-229. https://doi.org/10.1002/hep.22317
  33. Kisseleva T, Brenner DA. The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis. J Hepatol 2012;56:965-972. https://doi.org/10.1016/j.jhep.2011.09.021
  34. Lorenzini S, Andreone P. Regenerative medicine and liver injury: what role for bone marrow derived stem cells? Curr Stem Cell Res Ther 2007;2:83-88. https://doi.org/10.2174/157488807779317026
  35. Jang YY, Collector MI, Baylin SB, Diehl AM, Sharkis SJ. Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol 2004;6:532-539. https://doi.org/10.1038/ncb1132
  36. Wang X, Willenbring H, Akkari Y, et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 2003;422:897-901. https://doi.org/10.1038/nature01531
  37. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004;40:1304-1311. https://doi.org/10.1002/hep.20452
  38. Wang L, Wang X, Wang L, et al. Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells. Gastroenterology 2012;143:1555-1563.e2. https://doi.org/10.1053/j.gastro.2012.08.008
  39. Qi X, Guo X, Su C. Clinical outcomes of the transplantation of stem cells from various human tissue sources in the management of liver cirrhosis: a systematic review and meta-analysis. Curr Stem Cell Res Ther 2015;10:166-180. https://doi.org/10.2174/1574888X09666141112114011

Cited by

  1. Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis vol.2018, pp.None, 2017, https://doi.org/10.1155/2018/4197857
  2. Long-term Outcome of Autologous Hematopoietic Stem Cell Infusion in Cirrhosis: Waning Effect over Time vol.8, pp.4, 2020, https://doi.org/10.14218/jcth.2020.00052